Genomic tests are part of the diagnostic spectrum to guide the indication for adjuvant chemotherapy in hormone receptor‐positive (HR+), human epidermal growth factor receptor 2‐negative (HER−) breast cancer (BC) patients. This evidence concerns the gene NR4A1 and breast cancer.